Mutation Analysis of Second Primary Tumors in the Head and Neck Cancer by Next Generation Sequencing

More than 90% of malignant tumors in the head and neck are squamous carcinomas. These patients are with an average survival rate of about 5 years. However, some of the head and neck cancer(HNC) patients had the poor survival rate because of development of second primary tumors. In this study, the sequencing was performed using the Illumina system and Sanger sequencing was used to validate all identified mutations. We analyzed primary and second primary tumors in HNC and identified 23 mutant verification only in second primary tumors; 32 mutant verification only in primary tumors; 38 mutant verification in both of them. This mutant verification only in second primary tumors might be the cause of the second primary oral cancer.

[1]  Hsi-Yuan Huang,et al.  Determination of the mutational landscape in Taiwanese patients with papillary thyroid cancer by whole-exome sequencing. , 2018, Human pathology.

[2]  Marc S. Williams,et al.  ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.

[3]  Jung Kim,et al.  The prevalence of DICER1 pathogenic variation in population databases , 2017, International journal of cancer.

[4]  Y. Ko,et al.  Somatic Mutations and Genetic Variants of NOTCH1 in Head and Neck Squamous Cell Carcinoma Occurrence and Development , 2016, Scientific Reports.

[5]  Brittney N. Keel,et al.  Comparison of Burrows-Wheeler Transform-Based Mapping Algorithms Used in High-Throughput Whole-Genome Sequencing: Application to Illumina Data for Livestock Genomes , 2018, Front. Genet..

[6]  Carole Fakhry,et al.  Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Michael R Hamblin,et al.  Low-level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 2: proposed applications and treatment protocols , 2016, Supportive Care in Cancer.

[8]  M. Boysen,et al.  Synchronous second primary tumors in 2,016 head and neck cancer patients: Role of symptom‐directed panendoscopy , 2011, The Laryngoscope.

[9]  J. Debus,et al.  COSMIC: A Regimen of Intensity Modulated Radiation Therapy Plus Dose-Escalated, Raster-Scanned Carbon Ion Boost for Malignant Salivary Gland Tumors: Results of the Prospective Phase 2 Trial. , 2015, International journal of radiation oncology, biology, physics.

[10]  Grace S. Shieh,et al.  Detection of Somatic Mutations in Exome Sequencing of Tumor-only Samples , 2017, Scientific Reports.

[11]  Ting-Yuan Liu,et al.  Arecoline inhibits and destabilizes agrin-induced acetylcholine receptor cluster formation in C2C12 myotubes. , 2013, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[12]  A. Becker,et al.  Exome sequencing in syndromic brain malformations identifies novel mutations in ACTB, and SLC9A6, and suggests BAZ1A as a new candidate gene. , 2018, Birth defects research.

[13]  J. Piccirillo,et al.  Incidence and Risk of Second Primary Malignant Neoplasm After a First Head and Neck Squamous Cell Carcinoma , 2018, JAMA otolaryngology-- head & neck surgery.

[14]  Q. Wei,et al.  Incidence and pattern of second primary malignancies in patients with index oropharyngeal cancers versus index nonoropharyngeal head and neck cancers , 2013, Cancer.

[15]  Abhishek Kumar,et al.  Pedigree based DNA sequencing pipeline for germline genomes of cancer families , 2016, Hereditary Cancer in Clinical Practice.

[16]  Heidi L Rehm,et al.  CORRIGENDUM: ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2017, Genetics in Medicine.

[17]  L. Kowalski,et al.  Second Primary Tumors in Patients with Head and Neck Cancer , 2011, Current oncology reports.